Sana Biotechnology, Inc. — Director's Dealing 2021

Feb 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Sana Biotechnology, Inc. (SANA)
CIK: 0001770121
Period of Report: 2021-02-03

Reporting Person: MacDonald James J. (See Remarks)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	335000	Direct
Common Stock	125000	Indirect
Common Stock	125000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.48	2030-01-26	Common Stock (118750)		Direct
Stock Option (Right to Buy)	$7.80	2030-11-08	Common Stock (162500)		Direct
Series A-1 Convertible Preferred Stock	$		Common Stock (93750)		Direct
Series B Convertible Preferred Stock	$		Common Stock (7812)		Indirect

Footnotes

F1: The option vests and becomes exercisable as to 25% of the underlying shares on February 14, 2021 and in 36 equal monthly installments thereafter.

F2: The option vests and becomes exercisable as to 25% of the underlying shares on February 15, 2022 and in 36 equal monthly installments thereafter.

F3: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering.

F4: The expiration date is not relevant to the conversion of these securities.